Please enable JS
UPDATES

INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER)

An Organization with Deep Ties to Insurance Companies

The Institute for Clinical and Economic Review (ICER) is an organization in the U.S. that evaluates drugs and their cost-effectiveness.

Though they claim to be un-biased and patient focused, ICER consistently ignores Patient Reported Outcome (PRO) data when compiling their reports, the results of which are framed in a way that benefits their funding partners in the insurance industry.


Quick facts:

  • ICER was formed with the backing of $430,000 in seed funding from the insurance industry
  • ICER received 77% of its disclosed funding in 2013 from the insurance sector
  • Eight of the nine directors listed on ICER’s 2014 tax filing previously worked in the insurance industry

Though GHLF challenges the validity of the reports altogether, ICER’s reports matter. More than half of insurance companies – including Express Scripts and Blue Shield of California – have been known to cite and consult ICER reports when publicly discussing coverage decisions.

It’s alarming that there isn’t any statutory oversight, fact-checking and worst of all, transparency within that process.

 

RECENT DEVELOPMENTS

img

GHLF Rebukes ICER Analysis on Osteoporosis Treatments

Apr 26/GHLF Staff
GHLF calls conclusions from ICER's draft on osteoporosis treatments anti-patient and methodologically flawed.
READ MORE
img

New report risks limiting patients’ access to drugs

Apr 10/GHLF Staff
A report on rheumatoid arthritis treatment released by ICER risks restricting patients’ drug access, critics say.
READ MORE
img

CreakyJoints Protests ICER’s Rheumatoid Arthritis Evidence Report

Mar 24/GHLF Staff
CreakyJoints offered its strong objection to the Institute for Clinical and Economic Review’s (ICER) Rheumatoid Arthritis: Evidence Report.
READ MORE

Join GHLF and the 50-State Network and help us include the patient voice on these important issues.

 

ARTICLES & PRESS RELEASES

Apr 26

GHLF Rebukes ICER Analysis on Osteoporosis Treatments

/ ICER

GHLF calls conclusions from ICER’s draft on osteoporosis treatments anti-patient and methodologically flawed.

⇀ READ MORE
Apr 10

New report risks limiting patients’ access to drugs

/ ICER

A report on rheumatoid arthritis treatment released by ICER risks restricting patients’ drug access, critics say.

⇀ READ MORE
Mar 24

CreakyJoints Protests ICER’s Rheumatoid Arthritis Evidence Report

/ arthritis ICER Press Releases

CreakyJoints offered its strong objection to the Institute for Clinical and Economic Review’s (ICER) Rheumatoid Arthritis: Evidence Report.

⇀ READ MORE